Jak zwiekszyc skutecznosc leczenia grzybicy paznokci?

• Autorzy: Nowicki R
• Języki publikacji: PL

Abstrakty

EN

Onychomycosis is a public health concern because of its high world wide prevalence and its potential for spread of fungal elements to others. About one half of all patients presenting to dermatologists' offices for nail disorders have onychomycosis. This kind of infection may impact upon physical, functional and emotional aspects of life. Onychomycosis can be treated with the new generation of oral antifungals. Efficacy rates for fingernail onychomycosis are high; however, for toenail onychomycosis, efficacy rates may range from 60% to 80%. Relapse rates have been estimated to be 15% to 20% measured at 2 years following therapy initiation. Because many factors may be associated with a suboptimal clinical response, consideration to measures that retlect the most appropriate pharmacologic and supportive regimens must be made in order to meet the challenge of onychomycosis cure. In some situations supplemcntal therapy consisting of extra antifungal or adjunctive (topical/surgical) therapy may be beneficial.

Słowa kluczowe

PL

grzybica paznokci; choroby czlowieka; parazytologia lekarska; skutecznosc; leczenie

• Wydawca: -
• Czasopismo: Wiadomości Parazytologiczne
• Rocznik: 2001
• Tom: 47
• Numer: 4
• Opis fizyczny: s.823-832,tab.,bibliogr.

Twórcy

autor

Nowicki R

• Akademia Medyczna, ul.Debinki 7, 80-211 Gdansk

Bibliografia

• ALKIEWICZ J. 1947. Transverse net in the diagnosis of onychornycosis. Arch. Dermatol. 58: 385-388.
• ANDRE., ACHTEN G. 1987. Onychornycosis. Int. J. Dermatol. 26: 481-490.
• BARAN R. 2000. Ciclopirox nail lacquer: The frst prescription topical therapy for onychomycosis - Introduction .J. Am. Acad. Dermatol. 43: 555-556.
• BARAN R., HAY R., HANEKE E., TOSTI A. 1999. Onychomycosis. Martin Dunitz Publishers. London: 6-74.
• BARAN R., DAWBE R., HANEKE E., TOSTI A. 1996. A text atlas of nail disorders. Martin Dunitz Ltd. Londo: 155-168.
• COHEN P. R., SCHER R. K. 1994. Topical and surgical treatment of onychomycosis. J. Am. Acad. Dermatol. 31: S74-S77.
• DANIEL III C. R., DANIEL M. P., ZAIAC M., ALLEVATO M., SULLIVAN S. 2000. Itraconazole vs. terbinafine against non-dermatophytes. 58th Annual Meeting AAD, San Francisco. Poster Abstract Book: 349.
• DEK-MAR M., DE OCARIZ S., ARENAS R., RANERO JUAREZ G. A., FARRERA ESPONDA F., MONROY RAMOS E. 2001. Frequency of toenail onychomycosis in patients with cutaneous manifestations of chronic venous insufficiency. Int. J. Dermatol. 40: 18-25.
• DEL ROSSO J. Q., GUPTA A. K., CONTE E. T. 1998. A currenl appraisal of intcrmittcnt therapy with oral antifungal agents. Does one size fit all?. Final Programme Fifth Annual International Summit on Cutaneous Antifungal Therapy. Singapore: 30.
• ELEWSKI B. E. 1999. Current status of intermittent therapy in fungal diseasc. 57th Annual Meeting AAD. New Orle ans. Poster Abstract Book: 318.
• ELEWSKI B. E. 1996. Diagnostic techniques for confirming onychomycosis. J. Am. Acad. Dermatol. 35: S6-S9.
• GUPTA A. K. 2000. Onychomycosis in the elderly. Drugs-Aging. 16: 397-407.
• GUPTA A. K. 2000. Strategies to improve cure rates when treating onychomycosis and reduce relapse rates. 58th Annual Meeting AAD, San Francisco. Poster Abstracr Book: 356.
• GUPTA A. K., BARAN R 2000. Ciclopirox nail lacquer solution 8%, in the 21st century. J. Am. Acad. Dermatol. 43: S96-S102.
• GUPTA A. K.,DANIEL III C. R. 1998. Onychomycosis: stralegies to reduce failure and recurrence. Cutis 62: 189-191.
• GUPTA A. K., DEL ROSSO J. Q. 1999. The role of intermittent therapies in the treatment of onychomycosis and other dermatomycoses. 57th Annual Meeting AAD, New Orleans, Poster Abstract Book: 328.
• GUPTA A. K., LAMBERT J., REYUZ J., SHEAR N. 2001. Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoscs. Eur. J. Dermatol. 11: 6-11.
• GUPTA A. K., SCHER R. K. 1997. Management of onychomycosis: a North American perspective. Dermatol. Therapy 3: 58-65.
• HANEKE E. 1991. Fungal infections of the nail. Sem. Dermatol. 10: 41-53
• HAY R. J., MOORE M. 1999. Mycology. w: ROOK A., WILKINSON D. S., EBLING F. J. G.: Textbook of dermatology on CD-ROM. VIth Edition Electronic Version. Blackwell Science Ltd. Oxford.
• KORTING H. C., SCHALLER M. 2001. Neue Entwicklungen in der medizinischen Mykologie. Hautarzt. 52: 91-97.
• NOWICKI R. 1998. Czy grzybica paznokci wciąż stanowi problem diagnostyczny? Kilka uwag na temat różnicowania onychomikoz. Mikol. Lek. 5: 247-254.
• NOWICKI R. 1997. Czy grzybica paznokci stanowi wciąż problem terapeutyczny? Przegl. Dermatol. 84: 159-168.
• PROCHACKI H.1975. Podstawy mikologii lekarskiej. PZWL. Warszawa.
• RASHID A., SCOTT E., RICHARDSON M. D. 1995. Early events in the invasion of the human nail plate by Trichophyton mentagrophytes. Br. J. Dermatol. 133: 932-940.
• RICH P. 2000. Onychomycosis and tinea pedis in patients with diabetes. J. Am. Acad. Dermatol. 43: S130-S134.
• ROBERTS D. T., EVANS E. G. V., ALLEN B. R. 1990. Fungal Nail Infection. Pocker Picture Guides. Gower Medical Publishing, London: 41-77.
• RYDER N. S., BIRNBAUM J. E. 1997. Pharmacology of systemie antifungal agents: Focus onoptimizing therapy for onychomycoses. Dermatol. Therapy 3: 9-21.
• SCHER R. K. 1996. Onychomycosis: a significant medical disordcer. J. Am. Acad. Dermatol. 35: S2-S5.
• SCHWARTZ R. A., JANNIGER C. K. 1996. Onychomycosis. Cutis 57: 67-81.
• WENIG J. A. 1995. The systemic treatment of onychomycosis. Clin. Pediatr. Med. Surg. 12: 263-274.